Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease

Lindgren, Ola LU ; Asp, Pernilla ; Sundlöv, Anna LU orcid ; Tennvall, Jan LU ; Shahida, Bushra LU ; Planck, Tereza LU ; Åsman, Peter LU and Lantz, Mikael LU (2019) In European Thyroid Journal 8(2). p.64-69
Abstract

Background: In Graves' disease (GD), immunocompetent cells infiltrate thyroid tissue with release of TSH-receptor antibodies (TRAb), and radioiodine treatment is known to elicit an immune response with an increase in TRAb. Objectives: The aim was to study if all patients treated with radioiodine respond with a release of TRAb, anti-thyroperoxidase (anti-TPO), and anti-thyroglobulin (anti-TG). Methods: This is a prospective observational study. GD patients (n = 131) were admitted for treatment with radioiodine. Thyroid antibodies were measured before and 3 months after iodine-131 treatment. Results: After 3 months, a fold change > 1.1 was found in 66% of the GD patients, while the remaining 34% did not have a change or decrease in in... (More)

Background: In Graves' disease (GD), immunocompetent cells infiltrate thyroid tissue with release of TSH-receptor antibodies (TRAb), and radioiodine treatment is known to elicit an immune response with an increase in TRAb. Objectives: The aim was to study if all patients treated with radioiodine respond with a release of TRAb, anti-thyroperoxidase (anti-TPO), and anti-thyroglobulin (anti-TG). Methods: This is a prospective observational study. GD patients (n = 131) were admitted for treatment with radioiodine. Thyroid antibodies were measured before and 3 months after iodine-131 treatment. Results: After 3 months, a fold change > 1.1 was found in 66% of the GD patients, while the remaining 34% did not have a change or decrease in in TRAb. Anti-TPO and anti-TG also increased; the former showed an increase in 73% and the latter of 52%, while 27 and 48% decreased/were unchanged. A significant positive correlation was found between TRAb and anti-TPO, but not between TRAb and anti-TG. In the group with an increase in TRAb, the median fold change was 5.1, but there were no additional effects of tobacco smoking. The proportion of females below the median age (51.5 years) was significantly higher in the group that increased in TRAb compared to the one that decreased/was unchanged (66 vs. 34%). Conclusions: Treatment with radioiodine elicits an increase in thyroid antibodies, but not in all GD patients. The proportion of responders varied and was affected by age, resulting in a stronger immune response at younger age. However, there were no additional effects of smoking.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Anti-TG, Anti-TPO, Graves' disease, Radioiodine, TRAb
in
European Thyroid Journal
volume
8
issue
2
pages
64 - 69
publisher
Karger
external identifiers
  • pmid:31192144
  • scopus:85059613374
ISSN
2235-0640
DOI
10.1159/000495504
language
English
LU publication?
yes
id
f7aa639e-41ac-44b3-8bc2-8fa395d911d2
date added to LUP
2019-01-18 12:00:16
date last changed
2024-03-18 23:13:54
@article{f7aa639e-41ac-44b3-8bc2-8fa395d911d2,
  abstract     = {{<p>Background: In Graves' disease (GD), immunocompetent cells infiltrate thyroid tissue with release of TSH-receptor antibodies (TRAb), and radioiodine treatment is known to elicit an immune response with an increase in TRAb. Objectives: The aim was to study if all patients treated with radioiodine respond with a release of TRAb, anti-thyroperoxidase (anti-TPO), and anti-thyroglobulin (anti-TG). Methods: This is a prospective observational study. GD patients (n = 131) were admitted for treatment with radioiodine. Thyroid antibodies were measured before and 3 months after iodine-131 treatment. Results: After 3 months, a fold change &gt; 1.1 was found in 66% of the GD patients, while the remaining 34% did not have a change or decrease in in TRAb. Anti-TPO and anti-TG also increased; the former showed an increase in 73% and the latter of 52%, while 27 and 48% decreased/were unchanged. A significant positive correlation was found between TRAb and anti-TPO, but not between TRAb and anti-TG. In the group with an increase in TRAb, the median fold change was 5.1, but there were no additional effects of tobacco smoking. The proportion of females below the median age (51.5 years) was significantly higher in the group that increased in TRAb compared to the one that decreased/was unchanged (66 vs. 34%). Conclusions: Treatment with radioiodine elicits an increase in thyroid antibodies, but not in all GD patients. The proportion of responders varied and was affected by age, resulting in a stronger immune response at younger age. However, there were no additional effects of smoking.</p>}},
  author       = {{Lindgren, Ola and Asp, Pernilla and Sundlöv, Anna and Tennvall, Jan and Shahida, Bushra and Planck, Tereza and Åsman, Peter and Lantz, Mikael}},
  issn         = {{2235-0640}},
  keywords     = {{Anti-TG; Anti-TPO; Graves' disease; Radioiodine; TRAb}},
  language     = {{eng}},
  month        = {{01}},
  number       = {{2}},
  pages        = {{64--69}},
  publisher    = {{Karger}},
  series       = {{European Thyroid Journal}},
  title        = {{The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease}},
  url          = {{http://dx.doi.org/10.1159/000495504}},
  doi          = {{10.1159/000495504}},
  volume       = {{8}},
  year         = {{2019}},
}